623 QIP: Introducing a Dedicated Ozurdex Clinic

Abstract Aim To assess the feasibility and benefits of establishing a dedicated clinic for Ozurdex™ (dexamethasone intravitreal implant) injections outside the Vitreo-Retinal (VR) theatre to improve care and optimize resources. Method A retrospective analysis was conducted on Ozurdex procedures performed at JCUH between October 2021 and October 2022. Data included indications, waiting times, theatre usage, and complications. Additionally, resource requirements for a dedicated clinic were evaluated, and underutilization of Theatre 28 was reviewed from October 2023 to March 2024. Results Over 135 Ozurdex injections were performed, with indications including uveitis (47.3%), diabetic macular edema (23.6%), and retinal vein occlusion (22.9%). Procedures required an average of 15 minutes per injection in VR theatres. Complications were reported in 5% of cases, including glaucoma and implant migration. Waiting times averaged 6 weeks. Analysis revealed Theatre 28 was underused, with four unused days per month, equivalent to eight sessions. Conclusions A dedicated Ozurdex clinic would reduce waiting times, improving treatment outcomes. It would free 3 hours of VR theatre time monthly, enabling 3–4 additional retinal surgeries. The clinic would also optimize resources like Theatre 28 and provide trainees with hands-on opportunities. These findings support the implementation of a dedicated clinic to enhance patient care, operational efficiency, and staff training at JCUH.